(+)-2-*d*-mandelate (1.6 g) was converted to the (+)-**2** base (0.93 g, 94%) of mp 219–222 °C, as described above for the enantiomer (−)-**2**. Recrystallization from EtOH gave fine needles of pure (+)-**2**: mp 225–226 °C; $[\alpha]^{27}{}_{D}$ +28.9° (*c* 1.14, 1 N HCl). Anal. ($C_{16}H_{23}NO$) C, H, N.

**(−)-1,4,12*β*-Trimethyl-10-hydroxy-2,3,4,5,6,7-hexahydro-1,6-methano-1*H*-4-benzazonine [(−)-3].** To a suspension of **3** (2.71 g, 11.05 mmol) in MeOH (40 mL) was added *d*-tartaric acid (0.83 g, 5.53 mmol) in MeOH (10 mL). The mixture was heated to solution and allowed to stand at room temperature for 5 h. The solid was filtered, washed with cold MeOH, and dried to give 1.1 g of fine cubes. Three recrystallizations from MeOH gave optically pure (−)-**3**-*d*-tartrate: yield 0.91 g (50.8%); mp 208–211 °C; $[\alpha]^{27}{}_{D}$ −17.7° (*c* 2.0, $H_2O$). Anal. ($C_{32}H_{46}N_2O_2 \cdot C_4H_6O_6$) C, H, N. The neutral tartrate (0.9 g) was dissolved in $H_2O$ (20 mL), basified with $NH_4OH$, filtered, washed with $H_2O$, and dried to give 0.67 g (97%) of (−)-**3**. Recrystallization from MeOH–$Me_2CO$ (9:1) gave pure (−)-**3** as prisms: mp 175–176 °C; $[\alpha]^{29}{}_{D}$ −34.3° (*c* 1.53, 1 N HCl). Anal. ($C_{16}H_{23}NO$) C, H, N.

**(+)-1,4,12*β*-Trimethyl-10-hydroxy-2,3,4,5,6,7-hexahydro-1,6-methano-1*H*-4-benzazonine [(+)-3].** The combined filtrates and washings from 0.9 g of (−)-**3**-*d*-tartrate were evaporated to a syrup and dissolved in $H_2O$ (50 mL), made alkaline with $NH_4OH$, filtered, washed with $H_2O$, and dried to give 1.8 g of a solid mixture of (±) and (+) bases. The mixed bases (1.8 g, 7.35 mmol) were heated to solution with *l*-tartaric acid (0.56 g, 3.73 mmol) in MeOH (30 mL). The solution was allowed to stand at room temperature for 6 h. The resulting crystals were filtered, washed with cold MeOH, and dried to give 1.1 g of fine cubes. Two recrystallizations from MeOH gave optically pure (+)-**3**-*l*-tartrate: yield 0.97 g (58%); mp 207–210 °C; $[\alpha]^{27}{}_{D}$ +17.4° (*c* 2.0, $H_2O$). Anal. ($C_{32}H_{46}N_2O_2 \cdot C_4H_6O_6$) C, H, N. The neutral tartrate (0.97 g) was converted to the (+)-**3** base (0.69 g, 99%) as described above for its enantiomer (−)-**3**. Recrystallization from MeOH–$Me_2CO$ (9:1) gave pure (+)-**3**: prisms; mp 173–175 °C; $[\alpha]^{29}{}_{D}$ +36.3° (*c* 1.53, 1 N HCl). Anal. ($C_{16}H_{23}NO$) C, H, N.

**Acknowledgment.** The authors thank Dr. Arthur E. Jacobson of NIH for aid in arranging for the hot-plate test for analgesic activity at the NIH and the monkey test for physical-dependence capacity at the University of Michigan and Medical College of Virginia.

## References and Notes

(1) S. Shiotani, T. Kometani, K. Mitsuhashi, T. Nozawa, A. Kurobe, and O. Futsukaichi, *J. Med. Chem.*, **19**, 803 (1976).

(2) E. L. May and N. B. Eddy, *J. Med. Chem.*, **9**, 851 (1966); J. H. Ager, A. E. Jacobson, and E. L. May, *ibid.*, **12**, 288 (1969); E. L. May and M. Takeda, *ibid.*, **13**, 805 (1970); K. C. Rice and A. E. Jacobson, *ibid.*, **19**, 430 (1976).

(3) A. F. Green, P. A. Young, and E. I. Godfrey, *Br. J. Pharmacol.*, **6**, 572 (1951); K. Takagi, T. Kameyama, and K. Yano, *Yakugaku Zasshi*, **78**, 553 (1959); A. Kasahara, H. Kojima, W. Tsukada, and Y. Osima, *Yakugaku Zasshi*, **88**, 606 (1968).

(4) Groups of ten albino male mice, dd strain, were tested at five dose levels. $ED_{50}$ and $LD_{50}$ values were calculated by the Lichfield–Wilcoxon method.[9]

(5) N. B. Eddy and D. Leimbach, *J. Pharmacol. Exp. Ther.*, **107**, 385 (1953); A. E. Jacobson and E. L. May, *J. Med. Chem.*, **8**, 563 (1965), see ref 8 therein.

(6) A. E. Jacobson, personal communication, NIH.

(7) L. S. Harris, personal communication, Medical College of Virginia.

(8) H. H. Swain, personal communication, University of Michigan.

(9) J. T. Lichfield and F. Wilcoxon, *J. Pharmacol.*, **96**, 99 (1949).

# *Additions and Corrections*

### 1978, Volume 21

**James Z. Ginos,* George C. Cotzias, and David Doroski:** New Dopaminergic and Potential Anti-Parkinson Compounds, N,N-Disubstituted *β*-(3,4-Dihydroxyphenyl)ethylamines..

Page 162. In Table III, the melting point for compound **25** should read as 136.5–137.5 °C, after crystallizing twice from absolute ethanol–ether.

### 1979, Volume 22

**Arthur E. Jacobson,* Kenner C. Rice, Jurgen Reden, Lillian Lupinacci, Arnold Brossi, Richard A. Streaty, and Werner A. Klee:** Paradoxical Effects of *N*-Cyanoalkyl Substituents upon the Activities of Several Classes of Opioids.

Page 329. In Table II, footnote *d* should read as follows: Binding constant from rat brain homogenates, in nmol/L.